Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Ruth Ladenstein; Ulrike Pötschger; Dominique Valteau-Couanet; Roberto Luksch; Victoria Castel; Shifra Ash; Geneviève Laureys; Penelope Brock; Jean Marie Michon; Cormac Owens; Toby Trahair; Godfrey Chi Fung Chan; Ellen Ruud; Henrik Schroeder; Maja Beck-Popovic; Günter Schreier; Hans Loibner; Peter F Ambros; Keith Holmes; Maria Rita Castellani; Mark Gaze; Alberto Garaventa; Andrew DJ Pearson; Holger N Lode

doi:10.3390/cancers12020309

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Shifra Ash, Geneviève Laureys, Penelope Brock, Jean Marie Michon, Cormac Owens, Toby Trahair, Godfrey Chi Fung Chan, Ellen Ruud, Henrik Schroeder, Maja Beck-Popovic, Günter Schreier, Hans Loibner, Peter F Ambros, Keith Holmes, Maria Rita CastellaniMark Gaze, Alberto Garaventa, Andrew DJ Pearson, Holger N Lode

Digital Health Information Systems

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	1-19
Seitenumfang	19
Fachzeitschrift	Cancers
Issue	2
DOIs	https://doi.org/10.3390/cancers12020309
Publikationsstatus	Veröffentlicht - 2020

Research Field

Exploration of Digital Health

Zugriff auf Dokument

10.3390/cancers12020309Lizenz: Nicht angegeben

Diese Publikation zitieren

Ladenstein, R., Pötschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Ash, S., Laureys, G., Brock, P., Michon, J. M., Owens, C., Trahair, T., Chan, G. C. F., Ruud, E., Schroeder, H., Beck-Popovic, M., Schreier, G., Loibner, H., Ambros, P. F., Holmes, K., ... Lode, H. N. (2020). Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers, (2), 1-19. https://doi.org/10.3390/cancers12020309

@article{99976bab4ce744d6a2fc121e3232e596,

title = "Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)",

author = "Ruth Ladenstein and Ulrike P{\"o}tschger and Dominique Valteau-Couanet and Roberto Luksch and Victoria Castel and Shifra Ash and Genevi{\`e}ve Laureys and Penelope Brock and Michon, {Jean Marie} and Cormac Owens and Toby Trahair and Chan, {Godfrey Chi Fung} and Ellen Ruud and Henrik Schroeder and Maja Beck-Popovic and G{\"u}nter Schreier and Hans Loibner and Ambros, {Peter F} and Keith Holmes and Castellani, {Maria Rita} and Mark Gaze and Alberto Garaventa and Pearson, {Andrew DJ} and Lode, {Holger N}",

year = "2020",

doi = "10.3390/cancers12020309",

language = "English",

pages = "1--19",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

Ladenstein, R, Pötschger, U, Valteau-Couanet, D, Luksch, R, Castel, V, Ash, S, Laureys, G, Brock, P, Michon, JM, Owens, C, Trahair, T, Chan, GCF, Ruud, E, Schroeder, H, Beck-Popovic, M, Schreier, G, Loibner, H, Ambros, PF, Holmes, K, Castellani, MR, Gaze, M, Garaventa, A, Pearson, ADJ & Lode, HN 2020, 'Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)', Cancers, Nr. 2, S. 1-19. https://doi.org/10.3390/cancers12020309

TY - JOUR

T1 - Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

AU - Ladenstein, Ruth

AU - Pötschger, Ulrike

AU - Valteau-Couanet, Dominique

AU - Luksch, Roberto

AU - Castel, Victoria

AU - Ash, Shifra

AU - Laureys, Geneviève

AU - Brock, Penelope

AU - Michon, Jean Marie

AU - Owens, Cormac

AU - Trahair, Toby

AU - Chan, Godfrey Chi Fung

AU - Ruud, Ellen

AU - Schroeder, Henrik

AU - Beck-Popovic, Maja

AU - Schreier, Günter

AU - Loibner, Hans

AU - Ambros, Peter F

AU - Holmes, Keith

AU - Castellani, Maria Rita

AU - Gaze, Mark

AU - Garaventa, Alberto

AU - Pearson, Andrew DJ

AU - Lode, Holger N

PY - 2020

Y1 - 2020

U2 - 10.3390/cancers12020309

DO - 10.3390/cancers12020309

M3 - Article

SN - 2072-6694

SP - 1

EP - 19

JO - Cancers

JF - Cancers

IS - 2

ER -